DDInter392 DDInter899
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Cladribine {u} (Compound) resembles {v} (Compound) Vidarabine
Cladribine {u} (Compound) resembles {v} (Compound) Nelarabine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Azacitidine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abacavir
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
Cladribine {u} (Compound) binds {v} (Gene) PNP
Cladribine {u} (Compound) upregulates {v} (Gene) RGS2
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
Cladribine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reserpine
Cladribine (Compound) resembles Vidarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Azacitidine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Cladribine (Compound) treats hematologic cancer (Disease)
Cladribine (Compound) binds PNP (Gene)
Cladribine (Compound) upregulates RGS2 (Gene)
Cladribine (Compound) downregulates PLK1 (Gene)
Cladribine (Compound) causes Cardiac disorder (Side Effect)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine